ATE411026T1 - Mittel zur behandlung der alzheimer-krankheit - Google Patents

Mittel zur behandlung der alzheimer-krankheit

Info

Publication number
ATE411026T1
ATE411026T1 AT88905083T AT88905083T ATE411026T1 AT E411026 T1 ATE411026 T1 AT E411026T1 AT 88905083 T AT88905083 T AT 88905083T AT 88905083 T AT88905083 T AT 88905083T AT E411026 T1 ATE411026 T1 AT E411026T1
Authority
AT
Austria
Prior art keywords
disease
alzheimer
agents
treatment
compounds
Prior art date
Application number
AT88905083T
Other languages
English (en)
Inventor
Madeleine Joullie
Original Assignee
Bonnie Davis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bonnie Davis filed Critical Bonnie Davis
Application granted granted Critical
Publication of ATE411026T1 publication Critical patent/ATE411026T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Compression Or Coding Systems Of Tv Signals (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Processing Of Meat And Fish (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Eye Examination Apparatus (AREA)
AT88905083T 1987-05-04 1988-05-04 Mittel zur behandlung der alzheimer-krankheit ATE411026T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4652287A 1987-05-04 1987-05-04
CA000569641A CA1338326C (en) 1987-05-04 1988-06-16 Compounds for the treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
ATE411026T1 true ATE411026T1 (de) 2008-10-15

Family

ID=42046403

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88905083T ATE411026T1 (de) 1987-05-04 1988-05-04 Mittel zur behandlung der alzheimer-krankheit

Country Status (10)

Country Link
EP (1) EP0363415B1 (de)
JP (1) JP2755403B2 (de)
KR (1) KR100195399B1 (de)
AT (1) ATE411026T1 (de)
AU (1) AU632458B2 (de)
CA (1) CA1338326C (de)
DE (1) DE3856594D1 (de)
DK (1) DK175839B1 (de)
FI (1) FI102756B (de)
WO (1) WO1988008708A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
DE69229781T2 (de) * 1991-05-14 2000-01-05 Ernir Snorrason Behandlung des ermüdungssyndroms mit cholinesteraseinhibitoren
US5153193A (en) 1991-10-01 1992-10-06 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs
US6323195B1 (en) * 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US6316439B1 (en) * 1993-10-15 2001-11-13 Aventis Pharamaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US6323196B1 (en) * 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
AT401058B (de) * 1994-10-21 1996-06-25 Waldheim Pharmazeutika Gmbh Verfahren zum herstellen von derivaten des 4a,5, 9,10,11,12,-hexahydro-6h-benzofuro(3a,-3,2-ef) (2)benzazepins
PL184590B1 (pl) * 1994-10-21 2002-11-29 Sanochemia Pharmazeutika Ag Sposób wytwarzania pochodnych a heksahydro H benzofuro[ a ef][ ] benzoazepiny sposób odbromowania tych pochodnych sposób wytwarzania związków typu N demetylobromo i epibromo galantaminy oraz nowe związki z określonego zbioru
US6407229B1 (en) 1994-10-21 2002-06-18 Sanochemia Pharmazeutika Ag Processes for the preparation of derivatives of 4a,5,9,10,11,12-hexahydro-6H-benzofuro-[3a,3,2-ef][2] benzazapine
GB9506843D0 (en) 1995-04-03 1995-05-24 Chiroscience Ltd Oxidative process and products thereof
GB9514821D0 (en) * 1995-07-19 1995-09-20 Sod Conseils Rech Applic Galanthamine derivatives
GB9519267D0 (en) * 1995-09-21 1995-11-22 Chiroscience Ltd Preparation of alkaloids
AT403803B (de) 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
AU2004242546B2 (en) * 1998-11-23 2008-05-15 Bonnie Davis Dosage formulations for acetylcholinesterase inhibitors
JP5558648B2 (ja) 1998-11-23 2014-07-23 デイビス、ボニー アセチルコリンエステラーゼ阻害剤のための投与製剤
OA11740A (en) 1998-12-24 2005-05-13 Janssen Pharmaceutica Nv Controlled release galantamine composition.
MXPA02005667A (es) 1999-12-10 2004-09-10 Bonnie Davis Analogos de galantamina y licoramina como moduladores de los receptores nicotinicos.
JP2003529602A (ja) 2000-03-31 2003-10-07 ザノヒェミア・ファルマツォイティカ・アーゲー ガランタミンの新規誘導体および類似体
US20030162770A1 (en) 2002-02-22 2003-08-28 Davis Bonnie M. Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
US20090253654A1 (en) 2005-09-22 2009-10-08 Galantos Pharma Gmbh Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
EP1777222A1 (de) * 2005-09-22 2007-04-25 Galantos Pharma GmbH Cholinesterase Inhibitoren mit erhöter Blut Hirn Schranke Permeabilität zur Behandlung von kognitiven Störungen
DE602006015338D1 (de) * 2005-09-22 2010-08-19 Galantos Pharma Gmbh Cholinerge enhancer mit verbesserter durchgängigkeit durch die blut-hirn-schranke zur behandlung von krankheiten, die mit kognitiven störungen einhergehen
CN102007129B (zh) 2008-04-14 2014-05-07 神经动力生命科学公司 用作治疗人类脑疾病的前药的雪花胺衍生物
WO2010036998A2 (en) 2008-09-29 2010-04-01 Abbott Laboratories Indole and indoline derivatives and methods of use thereof
US9625475B2 (en) 2008-09-29 2017-04-18 Abbvie Inc. Indole and indoline derivatives and methods of use thereof
EP2533645B1 (de) 2010-02-09 2016-07-27 The Johns Hopkins University Verfahren und zusammensetzungen zur verbesserung von kognitiven funktionen
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
CN104853755B (zh) 2012-12-13 2017-08-22 H.隆德贝克有限公司 包含沃替西汀和多奈哌齐的组合物
EP2968237A4 (de) 2013-03-15 2016-08-31 Univ Johns Hopkins Verfahren und zusammensetzungen zur verbesserung der kognitiven funktion
EP2968220B1 (de) 2013-03-15 2021-05-05 Agenebio, Inc. Verfahren und zusammensetzungen zur verbesserung von kognitiven funktionen
MX384391B (es) 2015-05-22 2025-03-14 Agenebio Inc Composiciones farmacéuticas de levetiracetam de liberación extendida.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3673177A (en) * 1970-05-04 1972-06-27 American Cyanamid Co Substituted 4-(anilinomethylene)-3-galanthamaninones
PL122665B1 (en) * 1978-11-21 1982-08-31 Edinen Zentar Chim Process for preparing novel dienones of narvedine type and their derivatives
US4663318A (en) * 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
NL8800350A (nl) * 1988-02-12 1989-09-01 Stichting Biomedical Research Synthetische galanthamine-derivaten, werkwijze voor het bereiden daarvan, en farmaceutische samenstellingen.

Also Published As

Publication number Publication date
DK549189A (da) 1990-01-03
EP0363415A1 (de) 1990-04-18
FI102756B1 (fi) 1999-02-15
CA1338326C (en) 1996-05-14
AU632458B2 (en) 1993-01-07
AU1808488A (en) 1988-12-06
FI895213A0 (fi) 1989-11-02
FI102756B (fi) 1999-02-15
JP2755403B2 (ja) 1998-05-20
EP0363415B1 (de) 2008-10-15
KR890701107A (ko) 1989-12-19
JPH02503794A (ja) 1990-11-08
WO1988008708A1 (en) 1988-11-17
DK175839B1 (da) 2005-03-21
EP0363415A4 (en) 1993-03-17
KR100195399B1 (ko) 1999-06-15
DK549189D0 (da) 1989-11-03
DE3856594D1 (de) 2008-11-27

Similar Documents

Publication Publication Date Title
ATE411026T1 (de) Mittel zur behandlung der alzheimer-krankheit
NL300140I1 (nl) Galanthamine, of verbindingen die eraan analoog zijn, voor behandeling van de ziekte van Alzheimer.
DE69124293D1 (de) Vorrichtung zur Behandlung von Wirbelsäulenerkrankungen
DE3774918D1 (de) Cancerostatisches mittel.
DE69022249D1 (de) Knochenwachsapplikator zur Behandlung von Knochengewebe.
DE122006000010I1 (de) Benzocyclobutyl- oder Indanyl-Alkyl-Amino-Alkyl substituierte 3- Benzazepin-2-ones, verwendbar in der Behandlung von kardiovaskularen Krankheiten
DE3779346D1 (de) Zusammensetzung zur behandlung der haut.
DE3870508D1 (de) Zusammensetzung zur behandlung des haares.
DE3782214D1 (de) Mittel zur behandlung des scheidenmilieus.
DK163287A (da) 1,4-diazepiner og farmaceutiske midler med indhold af saadanne forbindelser
ATE123024T1 (de) 4-aminopyridinderivate.
ATE173625T1 (de) Zusammensetzungen zur behandlung von hiv- infektionen
DE3854121D1 (de) Arzneimittelzusammensetzungen zur behandlung von psoriasis.
ATE106736T1 (de) Verwendung von dimethylpolysiloxan zur behandlung von erkrankungen des gastrointestinaltraktes.
DE59902666D1 (de) Edelfosin zur behandlung von hirntumoren
ATE5256T1 (de) Phenylpiperazinderivate von 1,3,4oxadiazolylphenolen, ihre herstellung und diese enthaltende therapeutische mittel.
DE2966809D1 (en) 3,4-diaza-bicyclo(4.1.0)hepten-2-ones-5, process for their preparation and therapeutical compositions containing them
DE3866653D1 (de) Zusammensetzung fuer die behandlung der epidermis.
DE69307702D1 (de) Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit
DE68914886D1 (de) Mittel zur Behandlung von Raynaud's Krankheit.
DE68918449D1 (de) Siliziumverbindungen zur behandlung von knochen.
ATE136776T1 (de) Verwendung von heptastigmin zur behandlung der zerebralen ictus
DE3776662D1 (de) Pharmazeutische zusammensetzungen zur behandlung von hyperproliferativer hautkrankheit.
DE69133542D1 (de) Katheter zur Behandlung von Prostaterkrankungen
ATE86857T1 (de) Transdermate magensafthemmende wirkstoffe zur behandlung von magen-darm-erkrankungen.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties